Ventyx Biosciences, Inc. (NASDAQ: VTYX) shares enjoy slight gains Friday. The San Diego-based clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that the first patient has been dosed in a Phase 2a trial of VTX3232 in patients with early Parkinson’s disease.“We are excited to initiate this trial of VTX3232 in patients with early Parkinson’s disease,” said Chief Medical Officer Mark Forman. “There is a compelling body of evidence from the literature…